- CA$15.13m
- CA$16.94m
Annual income statement for Izotropic, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.16 | 4.98 | 6.65 | 5.66 | 1.27 |
| Operating Profit | -1.16 | -4.98 | -6.65 | -5.66 | -1.27 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.16 | -4.98 | -6.65 | -5.66 | -1.56 |
| Net Income After Taxes | -1.16 | -4.98 | -6.65 | -5.66 | -1.56 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.16 | -4.98 | -6.65 | -5.66 | -1.56 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.16 | -4.98 | -6.65 | -5.66 | -1.56 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.046 | -0.141 | -0.154 | -0.113 | -0.037 |
| Dividends per Share |